Capivasertib - AstraZeneca
Alternative Names: AZD 5363; TruqapLatest Information Update: 28 Nov 2025
At a glance
- Originator Astex Therapeutics; Cancer Research Technology; The Institute of Cancer Research
- Developer AstraZeneca
- Class Antineoplastics; Piperidines; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HER2 negative breast cancer
- Phase III Prostate cancer; Triple negative breast cancer
- Phase II Breast cancer; Endometrial cancer; Gastric cancer; Meningioma; Non-Hodgkin's lymphoma
- Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- No development reported Diffuse large B cell lymphoma
- Discontinued Non-small cell lung cancer
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for phase-I development in Breast-cancer(In volunteers) in United Kingdom (IV, Infusion)
- 28 Nov 2025 No recent reports of development identified for phase-I development in Prostate-cancer(In volunteers) in United Kingdom (IV, Infusion)
- 28 Nov 2025 No recent reports of development identified for phase-I development in Prostate-cancer(In volunteers) in United Kingdom (PO, Liquid)